LiFT™ (Liquid-foam therapy) is a novel pulmonary delivery platform addressing two major unmet needs: COPD and resistant pneumonia. It uniformly distributes cells or antibiotics across the lungs in under 30 seconds, reaching obstructed regions. LiFT™ is intended to be used as the first practical solution for lung-wide cell delivery and delivers 50× higher antibiotic concentrations. COPD alone affects 14M Americans, positioning LiFT™ as a breakthrough in a $10B+ therapeutic market.